Gefitinib Plus Durvalumab in EGFR TKI–Naïve Patients With EGFR Mutation–Positive Locally Advanced/Metastatic NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
British Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Phase 1 Study of Gefitinib Combined With Durvalumab in EGFR TKI-Naive Patients With EGFR Mutation-Positive Locally Advanced/Metastatic Non-Small-Cell Lung Cancer
Br. J. Cancer 2020 Oct 05;[EPub Ahead of Print], BC Creelan, TC Yeh, SW Kim, N Nogami, DW Kim, LQM Chow, S Kanda, R Taylor, W Tang, M Tang, HK Angell, MP Roudier, M Marotti, DL GibbonsFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.